Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/77560
| Title: | 1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? | Authors: | Rodriguez Abreu, D. Garassino, M.C. Esteban, E. Speranza, G. Felip, E. Domine, M. Hochmair, M.J. Powell, S.F. Cheng, S.Y.-S. Bischoff, H. Peled, N. Hui, R. Reck, M. Garon, E.B. Boyer, M. Grossi, F. Jennens, R. Yang, J. Pietanza, M.C. Gadgeel, S.M. |
UNESCO Clasification: | 320101 Oncología | Issue Date: | 2018 | Journal: | Annals of Oncology | Conference: | European-Society-for-Medical-Oncology Asia Congress | Abstract: | In KEYNOTE-189 (NCT02578680), pembro plus pem and platinum provided superior OS (HR 0.49, P < .00001) and PFS (HR 0.52, P < .00001) and had manageable safety vs placebo plus pem and platinum as first-line therapy for metastatic nonsquamous NSCLC. In an exploratory analysis, we assessed outcomes by investigator’s choice of carboplatin (carbo) or cisplatin (cis). | URI: | http://hdl.handle.net/10553/77560 | ISSN: | 0923-7534 | DOI: | 10.1093/annonc/mdy292.086 | Source: | Annals of Oncology [0923-7534], n. 29 (supl. 8) |
| Appears in Collections: | Actas de congresos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.